PMID- 37846340
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20231020
IS  - 2590-0293 (Electronic)
IS  - 2096-3602 (Print)
IS  - 2590-0293 (Linking)
VI  - 6
IP  - 3
DP  - 2023 Aug
TI  - Microwave ablation combined with transarterial chemoembolization containing 
      doxorubicin hydrochloride liposome for treating primary and metastatic liver 
      cancers.
PG  - 121-125
LID - 10.1016/j.jimed.2023.07.002 [doi]
AB  - AIMS: To determine the safety and efficacy of microwave ablation (MWA) and 
      transarterial chemoembolization (TACE) with doxorubicin hydrochloride liposome 
      (DHL) in patients with primary liver cancer (PLC) and metastatic liver cancer 
      (MLC). MATERIALS AND METHODS: The medical records of patients with primary or 
      metastatic liver cancer who underwent MWA combined with TACE containing DHL from 
      March 2019 to March 2022 were collected and analyzed. Treatment-related adverse 
      events (AEs) were recorded. Local tumor response was evaluated according to the 
      modified RECIST criteria. Local tumor progression-free survival (LTPFS) and 
      overall survival (OS) were calculated using the Kaplan-Meier method. RESULTS: 
      Altogether, 96 patients with liver cancer were included (PLC, n ​= ​45; MLC, 
      n ​= ​51). Forty (41.7%) patients experienced AEs during treatment, and eight 
      (8.3%) patients developed grade 3 AEs. Compared to before treatment, the serum 
      total bilirubin level and neutrophil to lymphocyte ratio significantly increased 
      after treatment. The median LTPFS was 14.5 months in patients with PLC and 10.7 
      months in patients with MLC. The median OS was not reached in patients with PLC 
      or MLC. The 1-month and 3-month disease control rates reached more than 80% in 
      both groups. CONCLUSION: MWA combined with TACE with DHL may be a safe and 
      effective method for the treatment of liver cancer.
CI  - (c) 2023 Shanghai Journal of Interventional Radiology Press. Publishing services by 
      Elsevier B.V. on behalf of KeAi Communications Co. Ltd.
FAU - Shi, Qin
AU  - Shi Q
AD  - Department of Interventional Radiology, Zhongshan Hospital, Fudan University, 
      Shanghai, 200032, China.
AD  - Shanghai Institution of Medical Imaging, Shanghai, 200032, China.
AD  - National Clinical Research Center for Interventional Medicine, Zhongshan 
      Hospital, Fudan University, Shanghai, 200032, China.
FAU - Zhang, Zihan
AU  - Zhang Z
AD  - Department of Interventional Radiology, Zhongshan Hospital, Fudan University, 
      Shanghai, 200032, China.
AD  - Shanghai Institution of Medical Imaging, Shanghai, 200032, China.
AD  - National Clinical Research Center for Interventional Medicine, Zhongshan 
      Hospital, Fudan University, Shanghai, 200032, China.
FAU - Zhang, Wen
AU  - Zhang W
AD  - Department of Interventional Radiology, Zhongshan Hospital, Fudan University, 
      Shanghai, 200032, China.
AD  - Shanghai Institution of Medical Imaging, Shanghai, 200032, China.
AD  - National Clinical Research Center for Interventional Medicine, Zhongshan 
      Hospital, Fudan University, Shanghai, 200032, China.
FAU - Ma, Jingqin
AU  - Ma J
AD  - Department of Interventional Radiology, Zhongshan Hospital, Fudan University, 
      Shanghai, 200032, China.
AD  - Shanghai Institution of Medical Imaging, Shanghai, 200032, China.
AD  - National Clinical Research Center for Interventional Medicine, Zhongshan 
      Hospital, Fudan University, Shanghai, 200032, China.
FAU - Yang, Minjie
AU  - Yang M
AD  - Department of Interventional Radiology, Zhongshan Hospital, Fudan University, 
      Shanghai, 200032, China.
AD  - Shanghai Institution of Medical Imaging, Shanghai, 200032, China.
AD  - National Clinical Research Center for Interventional Medicine, Zhongshan 
      Hospital, Fudan University, Shanghai, 200032, China.
FAU - Luo, Jianjun
AU  - Luo J
AD  - Department of Interventional Radiology, Zhongshan Hospital, Fudan University, 
      Shanghai, 200032, China.
AD  - Shanghai Institution of Medical Imaging, Shanghai, 200032, China.
AD  - National Clinical Research Center for Interventional Medicine, Zhongshan 
      Hospital, Fudan University, Shanghai, 200032, China.
FAU - Liu, Lingxiao
AU  - Liu L
AD  - Department of Interventional Radiology, Zhongshan Hospital, Fudan University, 
      Shanghai, 200032, China.
AD  - Shanghai Institution of Medical Imaging, Shanghai, 200032, China.
AD  - National Clinical Research Center for Interventional Medicine, Zhongshan 
      Hospital, Fudan University, Shanghai, 200032, China.
FAU - Yan, Zhiping
AU  - Yan Z
AD  - Department of Interventional Radiology, Zhongshan Hospital, Fudan University, 
      Shanghai, 200032, China.
AD  - Shanghai Institution of Medical Imaging, Shanghai, 200032, China.
AD  - National Clinical Research Center for Interventional Medicine, Zhongshan 
      Hospital, Fudan University, Shanghai, 200032, China.
LA  - eng
PT  - Journal Article
DEP - 20230716
PL  - China
TA  - J Interv Med
JT  - Journal of interventional medicine
JID - 9918265602006676
PMC - PMC10577058
OTO - NOTNLM
OT  - Doxorubicin hydrochloride liposome
OT  - Liver cancer
OT  - Microwave ablation
OT  - Transarterial chemoembolization
COIS- Zhiping Yan is Aaaociate Editors-in-chief for Journal of Interventional Medicine 
      and was not involved in the editorial review or the decision to publish this 
      article. All authors declare that there are no competing interests.
EDAT- 2023/10/17 06:43
MHDA- 2023/10/17 06:44
PMCR- 2023/07/16
CRDT- 2023/10/17 03:51
PHST- 2023/04/12 00:00 [received]
PHST- 2023/07/05 00:00 [revised]
PHST- 2023/07/08 00:00 [accepted]
PHST- 2023/10/17 06:44 [medline]
PHST- 2023/10/17 06:43 [pubmed]
PHST- 2023/10/17 03:51 [entrez]
PHST- 2023/07/16 00:00 [pmc-release]
AID - S2096-3602(23)00034-0 [pii]
AID - 10.1016/j.jimed.2023.07.002 [doi]
PST - epublish
SO  - J Interv Med. 2023 Jul 16;6(3):121-125. doi: 10.1016/j.jimed.2023.07.002. 
      eCollection 2023 Aug.